David A. Siegel Relmada Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 326,200 shares of RLMD stock, worth $975,338. This represents 0.0% of its overall portfolio holdings.
Number of Shares
326,200
Previous 328,300
0.64%
Holding current value
$975,338
Previous $1.36 Million
11.55%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding RLMD
# of Institutions
101Shares Held
14.3MCall Options Held
82KPut Options Held
73.9K-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.76 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.24MShares$3.71 Million0.19% of portfolio
-
Vestal Point Capital, LP New York, NY1.2MShares$3.59 Million0.46% of portfolio
-
Acadian Asset Management LLC Boston, MA1.18MShares$3.53 Million0.02% of portfolio
-
Parsons Capital Management Inc974KShares$2.91 Million0.31% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $85.5M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...